Stealth Biotherapeutics Announces FDA Acceptance of New Drug Application for Elamipretide for the Treatment of Barth Syndrome

NEEDHAM, Mass., April 8, 2024 /PRNewswire/— Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news